Evidence map›Paper›PMID 40445522›Full record

SynthesisClinical rheumatology2025

Kidney involvement in VEXAS syndrome: insights from a rare case of secondary amyloidosis and systematic review of renal biopsy-confirmed reports.

Gabriel Ştefan, Andreea Niculescu, Simona Cinca, Corina Chiriac, Adrian Zugravu, Pavel Cristina, Razvan Adrian Ionescu, Valer Mihai Pompilian, Nicoleta Petre, Cristina Căpusa and 1 more

Abstract readCase ReportsSystematic Review
In one paragraph

Synthesis in Clinical rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Gabriel ŞtefanUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Andreea NiculescuUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania. calenic.andreea@gmail.com.ORCID http://orcid.org/0009-0003-6761-8956
Simona Cinca"Dr. Carol Davila" Teaching Hospital of Nephrology, Bucharest, Romania.
Corina Chiriac"Dr. Carol Davila" Teaching Hospital of Nephrology, Bucharest, Romania.
Adrian ZugravuUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Pavel CristinaInternal Medicine Clinic, "Colentina" Hospital, Bucharest, Romania.
Razvan Adrian IonescuUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Valer Mihai PompilianUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Nicoleta PetreUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Cristina CăpusaUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.
Simona StancuUniversity of Medicine and Pharmacy "Carol Davila", Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

VEXAS syndrome is a recently identified autoinflammatory disorder caused by somatic mutations in the UBA1 gene, leading to systemic inflammation and hematologic abnormalities. While its renal involvement remains poorly understood, reported cases suggest a diverse spectrum of kidney pathology. We present a 69-year-old male with a history of systemic inflammation who developed nephrotic syndrome and worsening kidney function. His disease course included recurrent fevers, pulmonary infiltrates, cutaneous vasculitis, and hematologic abnormalities. A kidney biopsy revealed secondary amyloidosis, indicating chronic inflammation. Genetic testing confirmed a UBA1 mutation (c.121A > G, p.Met41Val), establishing the diagnosis of VEXAS syndrome. Despite treatment with corticosteroids, cyclosporine, and interleukin-1 blockade, the patient deteriorated and ultimately succumbed to septic shock. A systematic review of biopsy-confirmed renal involvement in VEXAS syndrome identified 23 cases, with interstitial nephritis as the most frequent histopathologic finding, followed by vasculitis, IgA nephropathy, minimal change disease, and amyloidosis. Treatment responses varied, with limited efficacy of immunosuppressive therapies. This case highlights the under-recognized renal manifestations of VEXAS syndrome, demonstrating its diagnostic challenges and the need for heightened clinical suspicion. Further research is required to define optimal management strategies and improve patient outcomes.

Indexed as

AmyloidosisHereditary Autoinflammatory DiseasesKidneyKidney DiseasesAgedBiopsyFatal OutcomeHumansMaleMutationMyelodysplastic SyndromesNephrotic SyndromeSkin Diseases, GeneticKidney biopsySecondary amyloidosisUBA1 geneVEXAS syndrome

Identifiers

PMID40445522
PMCPMC12234580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.